CCL2 and inflammatory bowel disease: Several studies confirming the elevation of iNOS and MCP1 in IBD patients (74–78) as well as experimental colitis models (79, 80) and constitutive expression of iNOS worsen UC symptoms by direct cytotoxicity, neutrophil activation (81), widening blood vessels (82), and/or elevating nitrosamines production (83).